Data / Drug companies / Docetaxel
Docetaxel: 21 companies and 58 products in the FDA NDC directory
Docetaxel is listed in the FDA National Drug Code Directory by 21 companies, with 58 products in commercial distribution. 30 of the products (51.7%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection, solution; injection, solution, concentrate; injection, and the newest product started marketing on December 15, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 21
- Products
- 58
- Generic (ANDA) products
- 30 (51.7%)
- Application numbers
- 18
- Routes
- Intravenous
- Brand names
- Beizray, Docivyx
- openFDA record search
- api.fda.gov
Companies that list docetaxel
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Baxter Healthcare Corporation | 6 | injection, solution; injection | New drug applications (NDA) | November 27, 2025 |
| Hospira, Inc. | 6 | injection, solution | New drug applications (NDA) | June 28, 2021 |
| Dr. Reddy's Laboratories Inc. | 5 | injection, solution | Generic drugs (ANDA) | April 22, 2019 |
| Zydus Pharmaceuticals USA Inc. | 4 | injection, solution; kit | New drug applications (NDA) | December 15, 2025 |
| Amneal Pharmaceuticals LLC | 3 | injection | Generic drugs (ANDA) | January 19, 2018 |
| Avyxa Pharma, LLC | 3 | injection, solution | New drug applications (NDA) | May 9, 2024 |
| Eugia US LLC | 3 | injection, solution | Generic drugs (ANDA) | June 25, 2021 |
| Gland Pharma Limited | 3 | injection | Generic drugs (ANDA) | July 1, 2021 |
| Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc. | 3 | injection | Generic drugs (ANDA) | December 15, 2024 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 3 | injection, solution, concentrate | Generic drugs (ANDA) | August 9, 2017 |
| Sanofi-Aventis U.S. LLC | 3 | injection, solution, concentrate | Authorized generics (NDA) | October 23, 2016 |
| Sun Pharmaceutical Industries, Inc. | 3 | injection, solution | New drug applications (NDA) | November 26, 2020 |
| Actavis Pharma, Inc. | 2 | injection, solution, concentrate | New drug applications (NDA) | September 1, 2014 |
| Hikma Pharmaceuticals USA Inc. | 2 | injection, solution, concentrate | Generic drugs (ANDA) | January 14, 2021 |
| Meitheal Pharmaceuticals Inc. | 2 | injection, solution, concentrate | Generic drugs (ANDA) | May 13, 2025 |
| Zhuhai Beihai Biotech Co., Ltd. | 2 | injection, solution | New drug applications (NDA) | December 15, 2025 |
| Accord Healthcare Inc. | 1 | injection, solution, concentrate | New drug applications (NDA) | May 30, 2013 |
| Alembic Pharmaceuticals Inc. | 1 | injection | Generic drugs (ANDA) | February 28, 2023 |
| Alembic Pharmaceuticals Limited | 1 | injection | Generic drugs (ANDA) | February 28, 2023 |
| Mylan Institutional LLC | 1 | injection, solution, concentrate | Generic drugs (ANDA) | June 18, 2019 |
| Sandoz Inc | 1 | injection, solution | New drug applications (NDA) | June 29, 2011 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 28 | 48.3% |
| Injection, solution, concentrate | 14 | 24.1% |
| Injection | 14 | 24.1% |
| Kit | 2 | 3.4% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 30 | 51.7% |
| New drug applications (NDA) | 25 | 43.1% |
| Authorized generics (NDA) | 3 | 5.2% |
Pharmacologic classes
| Class | Products |
|---|---|
| Microtubule Inhibitor | 56 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.